Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism
Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 590 | $50,038 | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | $12,887,302.92 | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | $1,062,243.06 | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | $73,176.91 | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | $6,044.11 | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | $1,805,125.51 | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $85.13 | 277 | $23,581.01 | 26,569 | 2025-10-15 | Filing | |
| $85.54 | 3,501 | $299,475.54 | 26,569 | 2025-10-03 | Filing | |
| $87.65 | 599 | $52,502.35 | 33,200 | 2025-10-02 | Filing | |
| $83.15 | 278 | $23,115.70 | 33,200 | 2025-09-16 | Filing | |
| $84.97 | 598 | $50,812.06 | 33,200 | 2025-09-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,319,388 | $196,707,292 | 0.28% | |
| 2. | 1,761,171 | $149,364,913 | 0.51% | |
| 3. | 1,248,642 | $105,897,328 | 0.27% | |
| 4. | 768,325 | $65,161,643 | 0.42% | |
| 5. | 371,856 | $31,537,108 | 0.03% |
News See All
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions
Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward trend.
Jim Cramer Talked About These Relatively 19 Cheap S&P 500 Stocks
On Monday, Jim Cramer, host of Mad Money, highlighted a group of relatively inexpensive stocks that caught his attention, focusing specifically on names within the S&P 500 across several sectors.
Incyte's Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions
Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now.
12 Best Innovative Stocks to Buy Now
On September 16, Lauren Goodwin, New York Life Investments chief market strategist, joined 'Closing Bell' on CNBC to suggest that the market's rally will remain healthy through year-end.
Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT
Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Incyte Corporation (INCY) Advances KRAS Cancer Program
Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical company based in Wilmington, Delaware, is strengthening its position as a leader in oncology and autoimmune therapies.
Hedge Fund Resource Center Billionaire Hedge Funds
